Loading clinical trials...
Loading clinical trials...
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
Conditions
Interventions
Tivozanib
Nivolumab
Locations
139
United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Chao Family Comprehensive Cancer Center, UC Irvine
Irvine, California, United States
University of California San Diego
La Jolla, California, United States
Leland Stanford Junior University
Redwood City, California, United States
Kaiser Permanente Riverside Medical Center
Riverside, California, United States
US Oncology - Rocky Mountain Cancer Centers - Midtown
Denver, Colorado, United States
Start Date
September 9, 2021
Primary Completion Date
September 30, 2025
Completion Date
December 30, 2025
Last Updated
August 22, 2025
NCT05969860
NCT07227402
NCT04693377
NCT07117227
NCT06500455
NCT06863311
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions